Roche (OTCMKTS:RHHVF) Given Buy Rating at The Goldman Sachs Group

Roche (OTCMKTS:RHHVF)‘s stock had its “buy” rating restated by stock analysts at The Goldman Sachs Group in a research report issued to clients and investors on Friday, AnalystRatings.com reports.

A number of other brokerages have also recently weighed in on RHHVF. UBS Group restated a “hold” rating on shares of Roche in a research report on Tuesday, March 23rd. JPMorgan Chase & Co. restated a “hold” rating on shares of Roche in a research report on Monday, April 19th. Barclays restated a “buy” rating on shares of Roche in a research report on Wednesday, April 21st. Finally, Sanford C. Bernstein reaffirmed a “buy” rating on shares of Roche in a research note on Wednesday, April 21st. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold”.

Shares of RHHVF stock opened at $375.20 on Friday. Roche has a fifty-two week low of $308.57 and a fifty-two week high of $388.50. The firm has a fifty day moving average price of $338.35.

Roche Company Profile

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation.

Featured Article: Blue-Chip Stocks

Analyst Recommendations for Roche (OTCMKTS:RHHVF)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.